drugset / Trial / NCT03289650

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650

Phase 3 Completed 29 enrolled Lorenzo Gallon
RandomizedParallel-groupOpen-labelTreatment

Summary

The overall aim of the study is to prospectively investigate the impact of two maintenance calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and twice-daily tacrolimus on subpopulations of T and B cells and alloreactive T cells as well as on renal allograft function.

Timeline

Start
2017-09-05
Primary completion
2021-02-23
Completion
2021-02-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule
Comparator Tacrolimus Small molecule Oral